Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine > News > How a Simple Photo Can Help Predict Survival in Cancer Patients: The FaceAge AI
  • News

How a Simple Photo Can Help Predict Survival in Cancer Patients: The FaceAge AI

  • 12 August 2025
  • Janet Fricker
How a Simple Photo Can Help Predict Survival in Cancer Patients: The FaceAge AI
Total
0
Shares
0
0
0
0
0

A deep learning model using biological age estimations from photographs improved physicians’ survival predictions in patients with incurable cancer receiving palliative care. The study, published in Lancet Digital Health, found that the faces of cancer patients averaged five years older than their chronological age, and that looking older was associated with worse outcomes for several types of cancer.

“This work demonstrates that a photo, like a simple selfie, contains important information that could help to inform clinical decision-making and care plans for patients and clinicians. How old someone looks compared to their chronological age really matters – individuals with face ages younger than their chronological ages do significantly better after cancer therapy,” says Hugo Aerts to CancerWorld, the co-senior author, who is Director of the Artificial Intelligence in Medicine Programme at Harvard Medicine School. The study, to the best of his knowledge, represents the first to validate a deep learning model exploring the association between estimated biological facial age and clinical outcomes.

In clinical practice, the overall first impression gained by the health care professional plays an important role in estimating the patient’s prognosis and balancing the benefits and risks of different treatments. This ‘eye ball’ approach, however, is a subjective assessment of functional status or fragility that only provides a rough estimate of biological age. 

“Therefore, there is a compelling need for quantitative methods to improve patient stratification and support physicians in this complex decision-making process for appropriate treatment selection,” write the authors. A person’s biological age, they hypothesised, is reflected in their facial characteristics, leading to the suggestion that deep learning algorithms could be developed to capture this information automatically. The result was the creation of FaceAge AI, a tool that uses ‘convolutional neural networks’ to quantify facial features and predict face age. To operate, FaceAge only requires a face photo (like a selfie) taken by any standard webcam or smartphone.

For the current study, Aerts and colleagues leveraged deep learning and facial technologies to train FaceAge. First, the tool was trained on 56,304 facial images obtained from the IMDb-Wiki database (the largest publicly available dataset of face images together with gender and age labels). It was assumed that people included in the cohort were of average health and that chronological age closely matched biological age. Next, the tool was validated on 2,547 faces from UTKFace (a dataset of 20,000 face images of people aged 0 to 116 years, together with annotations of age, gender, and ethnicity).

The clinical utility of the tool was then validated on data from 6,196 patients with cancer diagnoses from institutions in the US and the Netherlands, using photographs routinely taken at the start of radiotherapy treatment. FaceAge estimates in the cancer cohorts were compared with a non-cancerous reference cohort of 535 individuals. To assess the prognostic relevance of FaceAge, the team performed Kaplan-Meier survival analysis and Cox modelling, adjusting for clinical covariates. The team also assessed the performance of FaceAge in patients with metastatic cancer receiving palliative treatment at the end of life by incorporating FaceAge into clinical prediction models. Finally, to evaluate whether FaceAge has the potential to be a biomarker for molecular ageing, the team conducted a gene-based analysis of patients with non-small-cell lung cancer to assess associations with 22 genes linked to senescence.

Results showed that on average, patients with cancer looked older than their chronological age, with a mean increase of 4.70 years with respect to the non-cancerous reference cohort (P<0.0001).

Furthermore, older biological age than the patient’s real chronological age correlated with worse overall survival in a pan-cancer cohort (HR 1.151, P=0.013), a thoracic cancer cohort (HR 1.117, P =0.021), and a palliative cohort (HR 1.117, P=0.021).

In patients with incurable cancers receiving palliative treatments, introducing FaceAge improved physicians’ survival predictions. Area under the curve (a measure of model performance) increased from 0.74 [95% CI 0.70 – 0.78] to 0.8 [0.76-0.83); (P<0.0001).

The investigators observed an inverse association between CDK6 (a gene with an important role in regulating the G1/S checkpoint of the cell cycle) with FaceAge. By contrast, after adjusting for multiple comparisons, no genes showed significant associations with chronological age.

“Our results suggest that the facial characteristics visible in a photograph hold information about a person’s age that deep learning algorithms can use to enhance the accuracy of survival forecasts for patients with cancer,” conclude the authors. Notably, they add, FaceAge performed well in both patients treated for curative intent (with life expectancies of several years) and those at the end of life (with expected survivals of weeks to months).

“To test how clinicians might use FaceAge, we also showed that FaceAge significantly improved the performance of a validated clinical risk-scoring model for estimating survival in patients at the end of life who received palliative radiation treatment, a patient population for which improvements in treatment decision making using such models are critical,” write the authors. Evidence from SNP gene analysis that FaceAge correlates with molecular processes of cell-cycle regulation and cellular senescence supports the hypothesis that FaceAge is a biomarker related to biological ageing.

The authors acknowledge study limitations, such as the IMDb-Wiki database training cohort containing a substantial proportion of people in the public eye who might be more likely to have undergone cosmetic procedures influencing biological age estimations from photographs. Ethical concerns have been raised about the potential misuse of FaceAge to determine the insurability of prospective policyholders.

“Before clinical implementation, further work is needed to address these technical and ethical concerns, including optimisation and standardisation of training datasets to account for potential technical, health-related, and racial biases,” write the authors.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • AI biomarker development
  • AI cancer survival prediction
  • AI clinical decision support
  • biological age prediction
  • cancer ageing research
  • cancer patient risk stratification
  • cancer prognosis technology
  • CancerWorld
  • convolutional neural networks healthcare
  • deep learning in oncology
  • FaceAge AI
  • facial analysis cancer outcomes
  • Harvard Medical School AI research
  • molecular ageing biomarkers
  • oncology digital health
  • palliative care innovation
  • radiotherapy prognosis tools
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • Articles
  • Profiles

Jennifer Buell: Turning Living Cells into Living Medicines

  • 12 August 2025
  • Gevorg Tamamyan
View Post
Next Article
  • Articles
  • Profiles

Michel Goldman: A Teacher Until the End

  • 12 August 2025
  • Yeva Margaryan
View Post
You May Also Like
View Post
  • Articles
  • Medicine
  • News

Cancer Neuroscience: How Neurons Fuel Tumor Growth, and What it Means for Therapy

  • Sophie Fessl
  • 12 August 2025
View Post
  • News

BRCA1/BRCA2 Mutations Carriers at Greater Risk for Anaplastic Large Cell Lymphoma Associated with Breast Implants

  • Janet Fricker
  • 12 August 2025
View Post
  • Delivery of Care
  • News
  • Senza categoria

A Bold Step into Building Africa’s Cancer Atlas

  • Esther Nakkazi
  • 22 July 2025
View Post
  • News

Cannabis Use is Linked to Increased Mortality in Colon Cancer Patients

  • Janet Fricker
  • 22 July 2025
View Post
  • News

How a Brain-Destroying Protein Became Cancer’s Ally: Alpha-Synuclein Emerges as a New Target in Melanoma

  • Janet Fricker
  • 4 July 2025
View Post
  • News

CancerWorld #105 (July 2025)

  • Yeva Margaryan
  • 2 July 2025
View Post
  • News

How a Chicken Egg Model Could Transform Pediatric Cancer Treatment in Canada

  • Victoria Forster
  • 20 June 2025
View Post
  • News

Microbiota-Derived Bile Acids as Androgen Receptor Antagonists Enhance Anti-Tumour Immunity

  • Janet Fricker
  • 19 June 2025
search
CancerWorld #105 Download CancerWorld #104 Download CancerWorld #103 Download CancerWorld #102 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Cancer Neuroscience: How Neurons Fuel Tumor Growth, and What it Means for Therapy
    • 12 August 2025
  • BRCA1/BRCA2 Mutations Carriers at Greater Risk for Anaplastic Large Cell Lymphoma Associated with Breast Implants
    • 12 August 2025
  • How a Simple Photo Can Help Predict Survival in Cancer Patients: The FaceAge AI
    • 12 August 2025
  • A Bold Step into Building Africa’s Cancer Atlas
    • 22 July 2025
  • Cannabis Use is Linked to Increased Mortality in Colon Cancer Patients
    • 22 July 2025
Article
  • Cancer Neuroscience: How Neurons Fuel Tumor Growth, and What it Means for Therapy
    • 12 August 2025
  • Michel Goldman: A Teacher Until the End
    • 12 August 2025
  • Jennifer Buell: Turning Living Cells into Living Medicines
    • 12 August 2025
Social

Would you follow us ?

Contents
  • Michel Goldman: A Teacher Until the End
    • 12 August 2025
  • Jennifer Buell: Turning Living Cells into Living Medicines
    • 12 August 2025
  • “Moving Mountains with Passion”: The Life and Legacy of Baroness Françoise Meunier
    • 22 July 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.